絞り込み

16640

広告

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological Malignancies.

著者 Sánchez R , Ayala R , Martínez-López J
Int J Mol Sci.2019 Jun 10 ; 20(11):.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Ultra-deep next-generation sequencing has emerged in recent years as an important diagnostic tool for the detection and follow-up of tumor burden in most of the known hematopoietic malignancies. Meticulous and high-throughput methods for the lowest possible quantified disease are needed to address the deficiencies of more classical techniques. Precision-based approaches will allow us to correctly stratify each patient based on the minimal residual disease (MRD) after a treatment cycle. In this review, we consider the most prominent ways to approach next-generation sequencing methodologies to follow-up MRD in hematological neoplasms.
PMID: 31185671 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード